Carmen B. Volkart - 24 May 2022 Form 4 Insider Report for ANTARES PHARMA, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 24 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2022, 17:23:24 UTC
Prior SEC filing: 04 Apr 2022
Next SEC filing: 05 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Lisa M. Kallebo as attorney-in-fact for Carmen B. Volkart

Key filing fact

Carmen B. Volkart filed Form 4 for ANTARES PHARMA, INC. on 26 May 2022.

Key facts

This page summarizes Carmen B. Volkart's Form 4 filing for ANTARES PHARMA, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2022, 17:23.

Change

Previous filing in this sequence was filed on 04 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATRS transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -55,916
Change %: -100%
Price
Shares after: 0
Date: 24 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 55,916
Exercise price: $3.48
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Carmen B. Volkart is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").

Footnote F2

(Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

Footnote F3

Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.